Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018
- PMID: 33422381
- DOI: 10.1016/j.vaccine.2020.12.046
Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018
Abstract
Background: Myopericarditis after vaccination has been sporadically reported in the medical literature. Here, we present a thorough descriptive analysis of reports to a national passive vaccine safety surveillance system (VAERS) of myopericarditis after vaccines licensed for use in the United States.
Methods: We identified U.S. reports of myopericarditis received by VAERS during 1990-2018 that met a published case definition for myopericarditis or were physician-diagnosed. We stratified analysis by age group (<19, 19-49, ≥50 years), describing reports by serious/non-serious status, sex, time to symptom onset after vaccination, vaccine(s) administered, and exposure to other known causes of myopericarditis. We used Empirical Bayesian data mining to detect disproportionate reporting of myopericarditis after vaccination.
Results: VAERS received 620,195 reports during 1990-2018: 708 (0.1%) met the case definition or were physician-diagnosed as myopericarditis. Most (79%) myopericarditis reports described males; 69% were serious; 72% had symptom onset ≤ 2 weeks postvaccination. Overall, smallpox (59%) and anthrax (23%) vaccines were most commonly reported. By age, among persons aged < 19 years, Haemophilus influenzae type b (22, 22%) and hepatitis B (18, 18%); among persons aged 19-49 years smallpox (387, 79%); among persons aged ≥ 50 years inactivated influenza (31, 36%) and live attenuated zoster (19, 22%) vaccines were most commonly reported. The vaccines most commonly reported remained unchanged when excluding 138 reports describing other known causes of myopericarditis. Data mining revealed disproportionate reporting of myopericarditis only after smallpox vaccine.
Conclusions: Despite the introduction of new vaccines over the years, myopericarditis remains rarely reported after vaccines licensed for use in the United States. In this analysis, myopericarditis was most commonly reported after smallpox vaccine, and less commonly after other vaccines.
Keywords: Adverse event; Myopericarditis; Surveillance; VAERS; Vaccine.
Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.Vaccine. 2020 Aug 18;38(37):5923-5926. doi: 10.1016/j.vaccine.2020.07.007. Epub 2020 Jul 21. Vaccine. 2020. PMID: 32709434 Review.
-
Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.Hum Vaccin Immunother. 2018;14(8):1963-1969. doi: 10.1080/21645515.2018.1456598. Epub 2018 May 18. Hum Vaccin Immunother. 2018. PMID: 29580194 Free PMC article.
-
Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22. Vaccine. 2014. PMID: 25258101
-
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2004 Apr;23(4):287-94. doi: 10.1097/00006454-200404000-00002. Pediatr Infect Dis J. 2004. PMID: 15071280 Review.
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
Cited by
-
COVID-19 mRNA Vaccination-Induced Myopericarditis in an Otherwise Healthy Young Male: An Evidence-Based Approach to Differentiating From Perimyocarditis.Cureus. 2024 May 9;16(5):e59999. doi: 10.7759/cureus.59999. eCollection 2024 May. Cureus. 2024. PMID: 38736762 Free PMC article.
-
Myocarditis in Athletes: Risk Factors and Relationship with Strenuous Exercise.Sports Med. 2024 Mar;54(3):607-621. doi: 10.1007/s40279-023-01969-z. Epub 2023 Dec 11. Sports Med. 2024. PMID: 38079080 Review.
-
Immediate and Long-Term Adverse Events of COVID-19 Vaccines: A One-Year Follow-Up Study From the Kurdistan Region of Iraq.Cureus. 2023 Oct 25;15(10):e47670. doi: 10.7759/cureus.47670. eCollection 2023 Oct. Cureus. 2023. PMID: 38021955 Free PMC article.
-
Myocarditis following Coronavirus vaccination.Clin Immunol Commun. 2022 Dec;2:162-164. doi: 10.1016/j.clicom.2022.11.001. Epub 2022 Nov 17. Clin Immunol Commun. 2022. PMID: 38013968 Free PMC article.
-
Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine.Vaccines (Basel). 2023 Nov 10;11(11):1708. doi: 10.3390/vaccines11111708. Vaccines (Basel). 2023. PMID: 38006040 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous